Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Common Equity (2022 - 2025)

Historic Common Equity for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $308.1 million.

  • Stoke Therapeutics' Common Equity rose 3273.92% to $308.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $308.1 million, marking a year-over-year increase of 3273.92%. This contributed to the annual value of $229.0 million for FY2024, which is 4352.83% up from last year.
  • Latest data reveals that Stoke Therapeutics reported Common Equity of $308.1 million as of Q3 2025, which was up 3273.92% from $334.9 million recorded in Q2 2025.
  • Stoke Therapeutics' 5-year Common Equity high stood at $350.1 million for Q1 2025, and its period low was $140.3 million during Q1 2024.
  • Moreover, its 4-year median value for Common Equity was $224.3 million (2022), whereas its average is $228.5 million.
  • As far as peak fluctuations go, Stoke Therapeutics' Common Equity crashed by 3436.5% in 2024, and later surged by 14944.35% in 2025.
  • Over the past 4 years, Stoke Therapeutics' Common Equity (Quarter) stood at $184.8 million in 2022, then decreased by 13.68% to $159.6 million in 2023, then soared by 43.53% to $229.0 million in 2024, then soared by 34.53% to $308.1 million in 2025.
  • Its Common Equity was $308.1 million in Q3 2025, compared to $334.9 million in Q2 2025 and $350.1 million in Q1 2025.